BC Extra | Jul 18, 2019
Financial News

July 17 Financial Quick Takes: Chipscreen's Shanghai listing advances; plus Avrobio, Repligen and Seer

Chipscreen clears hurdle for Shanghai IPO With registration of its application by China Securities Regulatory Commission, Shenzhen Chipscreen Biosciences Ltd. (Shenzhen, China) overcame the final hurdle for its proposed listing on Shanghai’s science and technology...
BC Extra | Jul 16, 2019
Clinical News

July 15 Clinical Quick Takes: Zejula meets in Phase III for 1L ovarian cancer; plus Capricor, Avrobio and NIH

Zejula improves 1L ovarian cancer PFS  Zejula niraparib met the primary endpoint in the Phase III PRIMA trial to treat first-line ovarian cancer following platinum chemotherapy, significantly improving progression-free survival regardless of patients' biomarker status...
BioCentury | Mar 8, 2019
Emerging Company Profile

Synbal: Gene driving on parallel tracks

Synbal is tapping new genetic approaches to develop both rodents with humanized metabolisms and cell therapies for lysosomal storage diseases. Ethan Bier, Valentino Gantz and Tsvi Goldenberg spun out Synbal Inc. from the University of...
BC Week In Review | Oct 5, 2018
Clinical News

Vector copy number declines over time in four Fabry disease patients who received Avrobio gene therapy

Avrobio Inc. (NASDAQ:AVRO) said peripheral blood average vector copy number (VCN) declined over time in four Fabry disease patients who received a single dose of gene therapy AVR-RD-01 in either a Phase I or Phase...
BC Extra | Oct 1, 2018
Clinical News

Avrobio falls on data for Fabry gene therapy

Avrobio Inc. (NASDAQ:AVRO) said peripheral blood average vector copy number (VCN) declined over time in four Fabry disease patients who received a single dose of gene therapy AVR-RD-01 in either a Phase I or Phase...
BC Week In Review | Jun 22, 2018
Financial News

IPO roundup: Avrobio, Aptinyx, Magenta, Kezar, Xeris

Five biopharmas priced IPOs late on June 20, raising a total of more than $460 million. Four of the five upsized their offerings to sell more shares than anticipated; one of those, Avrobio, also priced...
BC Extra | Jun 21, 2018
Financial News

Four companies in IPO quintet post first-day gains

Four of the five biopharmas that priced IPOs late Wednesday posted gains on Thursday. Cell therapy company Avrobio Inc. (NASDAQ:AVRO) had the biggest first-day bump, climbing $12.20 (64%) to $31.20, while three others posted double-digit...
BC Week In Review | Jun 1, 2018
Financial News

Avrobio proposes $86.3M NASDAQ IPO

Avrobio Inc. (Cambridge, Mass.) proposed on May 25 to raise $86.3 million in an IPO underwritten by Morgan Stanley, Cowen, Wells Fargo and Wedbush PacGrow. In February, the cell therapy company raised $60 million in...
BC Extra | May 25, 2018
Financial News

Eidos, Avrobio propose NASDAQ IPOs

Eidos Therapeutics Inc. (Palo Alto, Calif.) and Avrobio Inc. (Cambridge, Mass.) proposed NASDAQ IPOs on Friday. Eidos proposed to raise $115 million in an IPO underwritten by J.P. Morgan, BofA Merrill Lynch and Barclays. Last...
BioCentury | Feb 2, 2018
Finance

Building momentum

Avrobio Inc. parlayed positive clinical data and an aggressive in-licensing strategy into a $60 million series B round that will fund early clinical development of three long-acting lysosomal storage disease candidates. Cormorant Asset Management and...
Items per page:
1 - 10 of 12